Condition
Plaque Type Psoriasis
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 3 (2)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT02660580Phase 3Completed
MSB11022 in Moderate to Severe Chronic Plaque Psoriasis
NCT02016105Phase 3CompletedPrimary
Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira
NCT01646567Phase 1CompletedPrimary
SHP-141C in Plaque Type Psoriasis
Showing all 3 trials